What is Noetik?
Noetik is an innovative biotechnology company that harnesses the power of artificial intelligence, specifically self-supervised machine learning, combined with high-throughput spatial data. This unique approach is geared towards the development of novel cancer therapeutics. The company's focus on AI-native solutions positions it at the forefront of precision medicine, aiming to revolutionize treatment paradigms for oncological diseases.
How much funding has Noetik raised?
Noetik has raised a total of $54M across 2 funding rounds:
Angel/Seed
$14M
Series A
$40M
Angel/Seed (2023): $14M with participation from EPIC Ventures, North South Ventures, DCVC Management, 11.2 Capital, Zetta Venture Partners, Intermountain Ventures, and Catalio Capital Management
Series A (2024): $40M led by Polaris Partners, Khosla Ventures, and Wittington Ventures
Key Investors in Noetik
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors, providing coaching and resources for growth.
Khosla Ventures
Khosla Ventures is a venture capital firm known for investing in a wide range of technology sectors, including AI and biotechnology, supporting companies with disruptive potential.
Wittington Ventures
Wittington Investments Limited is a private Canadian company with diverse investments, indicating a strategic interest in established and growth-oriented enterprises.
What's next for Noetik?
With the recent infusion of major strategic capital, Noetik is poised for accelerated growth and the advancement of its therapeutic pipeline. This significant investment will likely fuel further research and development, clinical trial progression, and the scaling of its proprietary AI platform. The company's trajectory suggests a strong emphasis on translating its cutting-edge technological capabilities into tangible clinical benefits for cancer patients, solidifying its position in the competitive biotech landscape.
See full Noetik company page
